Drug intelligence / Profile preview

SCB-1022

Development stage: Phase 2
Lead developer: Clover Biopharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**SCB-1022** is an investigational bivalent recombinant protein subunit respiratory vaccine developed by Clover Biopharmaceuticals for prevention of disease caused by respiratory syncytial virus and human metapneumovirus. It combines prefusion-stabilized fusion protein trimer antigens from RSV and hMPV, produced using Clover's Trimer-Tag platform, to induce neutralizing immune responses against both viral pathogens. SCB-1022 has advanced from positive Phase 1 data in older adults into a Phase 2 trial in adults aged 60–85 years.

Targets

RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)

Beyond the preview

Go deeper on SCB-1022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCB-1022.

Explore the full profile